Figure 12

Role of ERK1/2 activation in IFNγ-induced ROS and NO production in BV-2 and HAPI microglial cells. Cells were treated with IFNγ (10 ng/ml) with or without the MEK1/2 inhibitor, U0126 (1.25 to 10 μM). (A) Representative Western blot demonstrated ability for U0126 to inhibit phosphorylation of ERK1/2 dose-dependently 4 h after IFNγ treatment. (B) For ROS production, BV-2 cells were pretreated with different concentrations of U0126 for 1 h prior to stimulation with IFNγ for 12 h. (C) For NO production, both BV-2 and HAPI cells were pretreated with different concentrations of U0126 for 1 h prior to stimulation with IFNγ for 16 h. Results are expressed as the mean ± SEM (n = 3), and significant difference from the respective IFNγ stimulated group was determined by one-way ANOVA followed by Dunnett’s tests, ** P < 0.01; *** P < 0.001.